|
See related Peg-Intron Redipen pre-filled pen information |
|
|
|
Manufacturer |
MSD |
|
Distributor |
Zuellig |
|
Contents |
Peginterferon α-2b |
|
Indications |
Treatment of Chronic Hepatitis B & C in patients ≥18 yr & have compensated liver disease.
Click to view Peg-Intron Redipen detailed prescribing infomation |
|
Dosage |
Treatment of Chronic Hepatitis C Monotherapy 0.5 or 1 mcg/kg SC once wkly for at least 6 mth. Continue for another 6 mth in patients who lost HCV-RNA at 6 mth. Combination therapy 1.5 mcg/kg/wk SC w/ ribavirin cap based on body wt: >105 kg 0.5 mL Peg-Intron 150 mcg/0.5 mL once wkly + ribavirin 1,400 mg/day, 86-105 kg 0.5 mL Peg-Intron 150 mcg/0.5 mL once wkly + ribavirin 1,200 mg/day, 81-85 kg 0.5 mL Peg-Intron 120 mcg/0.5 mL once wkly + ribavirin 1,200 mg/day, 76-80 kg 0.5 mL Peg-Intron 120 mcg/0.5 mL once wkly + ribavirin 1,000 mg/day, 65-75 kg 0.5 mL Peg-Intron 100 mcg/0.5 mL once wkly + ribavirin 1,000 mg/day, 51-64 kg 0.5 mL Peg-Intron 80 mcg/0.5 mL once wkly + ribavirin 800 mg/day, 40-50 kg 0.4 mL Peg-Intron 80 mcg/0.5 mL once wkly + ribavirin 800 mg/day, <40 kg 0.5 mL Peg-Intron 50 mcg/0.5 mL once wkly + ribavirin 800 mg/day. Duration of treatment: At least 6 mth. Genotype 1: Continue for another 6 mth in those who have negative HCV-RNA after 6 mth. In the subset of patients w/ genotype 1 infection & low viral load (<2,000,000 copies/mL) who became HCV-RNA negative at treatment wk 4 & remain HCV-RNA negative at wk 24, the treatment could either be stopped after this 24 wk treatment course or pursued for an additional 24 wk. Genotypes 2 or 3: Treat for 24 wk. Genotype 4: Same as genotype 1. HIV/HCV co-infection duration of treatment: 48 wk, regardless of genotype. Treatment of Chronic Hepatitis B 1 or 1.5 mcg/kg once wkly SC for 24 wk in HBe positive & for 48 wk in HBe negative. Dose should be selected based on the anticipated efficacy & safety. Patients w/ hard to treat genotypes C & D may benefit from the higher dose & longer duration.
Click to view Peg-Intron Redipen detailed prescribing infomation |
|
Overdosage |
View Peg-Intron Redipen overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Hypersensitivity to interferon. Autoimmune hepatitis or history of autoimmune disease. Decompensated liver disease or severe renal dysfunction (CrCl <50 mL/min). Pregnancy.
Click to view Peg-Intron Redipen detailed prescribing infomation |
|
Special Precautions |
Renal impairment. Patient who develop fatigue, somnolence or confusion during treatment are cautioned to avoid driving or operating machinery. History of CHF, MI &/or previous or current arrhythmic disorders. Any patient complaining of loss of visual acuity or visual field must have an eye exam. Monitor patient who develop psychiatric or CNS problems, including clinical depression, preexisting psoriatic disease. Lactation.
Click to view Peg-Intron Redipen detailed prescribing infomation |
|
Adverse Drug Reactions |
Headache, myalgia. Very commonly, inflammation at inj site, fatigue, rigors, fever, depression, arthralgia, nausea, alopecia, musculoskeletal pain, irritability, flu-like symptoms, insomnia, diarrhea, abdominal pain, asthenia, pharyngitis, wt decrease, anorexia, anxiety, impaired concentration, dizziness. Commonly, pruritus, dry skin, malaise, increase sweating, right upper quadrant pain, neutropenia, rash, vomiting, dry mouth, emotional lability, nervousness, dyspnea, viral infection, somnolence, thyroid disorder, chest pain, dyspepsia, flushing, paresthesia, coughing, agitation, sinusitis, hypertonia, hyperesthesia, blurred vision, confusion, flatulence, decreased libido, erythema, eye pain, apathy, hypoesthesia, loose stool, conjunctivitis, nasal congestion, constipation, vertigo, menorrhagia, menstrual disorder.
View ADR Monitoring Form |
|
Drug Interactions |
Drugs metabolized by CYP2C8/9 & CYP2D6.
View more drug interactions with Peg-Intron Redipen |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Peg-Intron Redipen detailed prescribing infomation |
|
Storage |
View Peg-Intron Redipen storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Peg-Intron Redipen description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Peg-Intron Redipen mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
